Business
NFL Biosciences Announces a Scientific Collaboration with McLean Hospital (Boston, USA) to Further Investigate the Mechanism of Action of NFL-101
MONTPELLIER, France, July 28, 2025--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 - ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today announces the launch of a scientific collaboration with McLean Hospital, a member of the Mass General Brigham healthcare system in Boston, USA. This new collaboration aims to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate
About this update from Nfl Biosciences Sa
[{"type":"text","content":"MONTPELLIER, France, July 28, 2025--(BUSINESS WIRE)--Regulatory News:","length":69,"tagName":"p"},{"type":"text","content":"NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 - ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today announces the launch of a scientific collaboration with McLean Hospital, a member of the Mass General Brigham healthcare system in Boston, USA. This new collaboration aims to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation.","length":470,"tagName":"p"},{"type":"text","content":"This collaboration follows studies conducted with the Georges Pompidou European Hospital (HEGP) and the French Alternative Energies and Atomic Energy Commission (CEA) which highlighted NFL-101’s ability to restore normal brain activity in regions associated with tobacco craving, particularly the thalamus, during withdrawal. This restoration proved to be both specific and sustained. These results suggest the existence of a unique mechanism of action involving an interaction between the immune system and the central nervous system, distinct from existing treatments that directly target nicotinic receptors.","length":611,"tagName":"p"},{"type":"text","content":"The studies conducted by McLean Hospital will explore in greater detail the links between this brain activity restoration and established biomarkers of tobacco addiction, with the objective of further characterizing NFL-101’s pharmacological profile. Three laboratories at McLean Hospital, will be involved in this project: the Integrative Neurochemistry Laboratory, the Behavioral Neuroimaging Laboratory, and the Behavioral Psychopharmacology Research Laboratory.","length":465,"tagName":"p"},{"type":"text","content":"This collaboration represents a strategic milestone aligned with the upcoming Phase III trial. It also supports NFL Biosciences' international expansion, particularly in the United States, through collaborations with world-renowned experts in addiction science. The results will further strengthen NFL Biosciences' regulatory submission. Launched at a pivotal time, this initiative contributes to the momentum of ongoing discussions with potential industrial partners.","length":476,"tagName":"p"},{"type":"text","content":"...